Dianthus Therapeutics (DNTH)
Dianthus Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
9.0M
Short interest
settlement 2026-10-15
10.2
Days to cover
+1.8 days vs prior
59.1%
Short share of volume
2026-11-02
176
Fails to deliver
settlement 2026-10-07
Wed 4 Nov
Next earnings
estimated date
-$26.1M
Insider flow, 90 days
0 buys, 30 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in DNTH is 8,986,958 shares, up 157,295 shares over the last month. Over the last 48 readings it ranged from 3,714,830 shares (28 November 2025) to 9,533,151 shares (30 June 2026). The latest reading sits at the top of that range. At the reported average volume of 883K shares a day that is 10.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/dnth" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 8,986,958 | -1.7% | 883,432 | 10.17 |
| 2026-09-30 | 9,140,581 | +3.5% | 1,098,229 | 8.32 |
| 2026-09-15 | 8,829,663 | +4.7% | 612,119 | 14.42 |
| 2026-08-31 | 8,429,902 | +0.1% | 550,760 | 15.31 |
| 2026-08-14 | 8,418,356 | +0.5% | 729,436 | 11.54 |
| 2026-07-31 | 8,378,963 | -9.1% | 882,872 | 9.49 |
| 2026-07-15 | 9,220,028 | -3.3% | 1,040,854 | 8.86 |
| 2026-06-30 | 9,533,151 | +36.6% | 1,741,670 | 5.47 |
| 2026-06-15 | 6,979,126 | +4.3% | 1,226,589 | 5.69 |
| 2026-05-29 | 6,690,110 | +4.0% | 615,010 | 10.88 |
| 2026-05-15 | 6,431,398 | -1.9% | 450,635 | 14.27 |
| 2026-04-30 | 6,552,520 | -0.2% | 463,515 | 14.14 |
| 2026-04-15 | 6,564,599 | -27.6% | 788,190 | 8.33 |
| 2026-03-31 | 9,069,811 | -1.4% | 1,233,092 | 7.36 |
| 2026-03-13 | 9,194,068 | +16.5% | 1,933,138 | 4.76 |
| 2026-02-27 | 7,893,078 | -2.6% | 570,316 | 13.84 |
| 2026-02-13 | 8,101,842 | -2.4% | 622,465 | 13.02 |
| 2026-01-30 | 8,299,074 | +12.5% | 1,014,214 | 8.18 |
| 2026-01-15 | 7,378,003 | +20.2% | 848,791 | 8.69 |
| 2025-12-31 | 6,136,786 | +47.4% | 750,490 | 8.18 |
| 2025-12-15 | 4,164,492 | +12.1% | 531,148 | 7.84 |
| 2025-11-28 | 3,714,830 | -9.0% | 917,555 | 4.05 |
| 2025-11-14 | 4,082,790 | +1.4% | 627,140 | 6.51 |
| 2025-10-31 | 4,028,355 | +7.6% | 474,309 | 8.49 |
| 2025-10-15 | 3,744,405 | -24.5% | 611,344 | 6.12 |
| 2025-09-30 | 4,959,621 | -3.2% | 734,065 | 6.76 |
| 2025-09-15 | 5,123,594 | -8.2% | 1,504,152 | 3.41 |
| 2025-08-29 | 5,579,726 | -6.8% | 428,045 | 13.04 |
| 2025-08-15 | 5,983,909 | -6.5% | 331,589 | 18.05 |
| 2025-07-31 | 6,399,026 | +4.8% | 318,705 | 20.08 |
| 2025-07-15 | 6,104,610 | -10.9% | 412,475 | 14.80 |
| 2025-06-30 | 6,853,406 | +2.5% | 296,513 | 23.11 |
| 2025-06-13 | 6,686,719 | +4.3% | 293,401 | 22.79 |
| 2025-05-30 | 6,408,417 | +0.6% | 272,509 | 23.52 |
| 2025-05-15 | 6,370,624 | +2.7% | 238,042 | 26.76 |
| 2025-04-30 | 6,203,875 | +5.1% | 268,928 | 23.07 |
| 2025-04-15 | 5,901,485 | +11.6% | 544,432 | 10.84 |
| 2025-03-31 | 5,288,265 | -5.1% | 484,527 | 10.91 |
| 2025-03-14 | 5,571,975 | +2.7% | 244,036 | 22.83 |
| 2025-02-28 | 5,423,503 | +2.1% | 225,781 | 24.02 |
| 2025-02-14 | 5,311,157 | -10.2% | 208,042 | 25.53 |
| 2025-01-31 | 5,911,283 | -0.2% | 213,666 | 27.67 |
| 2025-01-15 | 5,924,150 | -1.3% | 341,873 | 17.33 |
| 2024-12-31 | 6,002,847 | +6.0% | 193,073 | 31.09 |
| 2024-12-13 | 5,661,839 | +0.9% | 195,584 | 28.95 |
| 2024-11-29 | 5,613,833 | +3.1% | 220,244 | 25.49 |
| 2024-11-15 | 5,442,599 | +6.8% | 414,787 | 13.12 |
| 2024-10-31 | 5,096,640 | +7.8% | 148,198 | 34.39 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of DNTH volume is 59.1%, up 0.1 points over the last five sessions. Over the last 30 readings it ranged from 30.8% (22 October 2026) to 80.2% (27 October 2026). The latest reading is 5.3 points above the 30-session average of 53.8%, on 259K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 153K | 259K | 59.1% | 0 |
| 2026-10-30 | 111K | 213K | 51.9% | 0 |
| 2026-10-29 | 92K | 215K | 42.6% | 0 |
| 2026-10-28 | 121K | 253K | 47.9% | 0 |
| 2026-10-27 | 251K | 313K | 80.2% | 480 |
| 2026-10-26 | 71K | 120K | 59.0% | 0 |
| 2026-10-23 | 95K | 152K | 62.7% | 0 |
| 2026-10-22 | 156K | 506K | 30.8% | 30 |
| 2026-10-21 | 110K | 182K | 60.5% | 0 |
| 2026-10-20 | 281K | 620K | 45.3% | 293 |
| 2026-10-19 | 162K | 274K | 59.1% | 3,568 |
| 2026-10-16 | 239K | 475K | 50.3% | 625 |
| 2026-10-15 | 177K | 457K | 38.7% | 10,351 |
| 2026-10-14 | 149K | 376K | 39.8% | 0 |
| 2026-10-13 | 138K | 379K | 36.5% | 235 |
| 2026-10-12 | 84K | 118K | 71.6% | 0 |
| 2026-10-09 | 203K | 254K | 79.7% | 311 |
| 2026-10-08 | 158K | 364K | 43.4% | 75 |
| 2026-10-07 | 93K | 184K | 50.7% | 0 |
| 2026-10-06 | 246K | 439K | 56.1% | 1,263 |
| 2026-10-05 | 113K | 250K | 45.3% | 0 |
| 2026-10-02 | 213K | 274K | 77.6% | 5 |
| 2026-10-01 | 134K | 296K | 45.2% | 0 |
| 2026-09-30 | 216K | 322K | 66.9% | 4 |
| 2026-09-29 | 198K | 344K | 57.6% | 4 |
| 2026-09-28 | 136K | 264K | 51.5% | 0 |
| 2026-09-25 | 94K | 214K | 43.8% | 0 |
| 2026-09-24 | 155K | 334K | 46.4% | 84 |
| 2026-09-23 | 223K | 385K | 57.9% | 150 |
| 2026-09-22 | 139K | 249K | 55.9% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 7 October 2026, the fails-to-deliver balance in DNTH is 176 shares, down 736 shares over the last settlement date. Over the last 30 readings it ranged from 4 shares (12 June 2026) to 82,070 shares (17 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-07 | 176 | $85.40 | $15K |
| 2026-10-05 | 912 | $88.21 | $80K |
| 2026-09-22 | 7,783 | $96.47 | $751K |
| 2026-09-21 | 29,574 | $96.81 | $2.9M |
| 2026-09-17 | 82,070 | $102.49 | $8.4M |
| 2026-09-16 | 2,271 | $104.77 | $238K |
| 2026-09-09 | 198 | $109.13 | $22K |
| 2026-09-02 | 31,771 | $106.62 | $3.4M |
| 2026-08-26 | 18 | $112.11 | $2K |
| 2026-08-04 | 53 | $106.02 | $6K |
| 2026-07-16 | 22 | $99.91 | $2K |
| 2026-07-09 | 400 | $98.07 | $39K |
| 2026-07-08 | 54,605 | $95.76 | $5.2M |
| 2026-07-07 | 58 | $93.34 | $5K |
| 2026-07-02 | 35,982 | $90.21 | $3.2M |
| 2026-07-01 | 68 | $97.48 | $7K |
| 2026-06-30 | 2,697 | $95.68 | $258K |
| 2026-06-29 | 68,521 | $95.35 | $6.5M |
| 2026-06-26 | 6,760 | $91.57 | $619K |
| 2026-06-24 | 5 | $87.53 | $438 |
| 2026-06-22 | 10 | $82.49 | $825 |
| 2026-06-15 | 74 | $82.07 | $6K |
| 2026-06-12 | 4 | $76.45 | $306 |
| 2026-06-11 | 310 | $76.42 | $24K |
| 2026-06-10 | 3,224 | $84.57 | $273K |
| 2026-05-26 | 264 | $86.48 | $23K |
| 2026-05-21 | 5 | $88.72 | $444 |
| 2026-05-20 | 13,995 | $85.67 | $1.2M |
| 2026-05-15 | 761 | $85.34 | $65K |
| 2026-05-13 | 3,028 | $86.15 | $261K |
Insider trades
SEC Form 4, newest first. JSONInsiders at DNTH reported 30 open-market sells worth $26.1M in the last 90 days and no open-market buys. Latest filing: CARR EDWARD (CHIEF ACCOUNTING OFFICER) on 2026-09-17.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 700 | $104.39 | $73K | 0 |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 1K | $103.20 | $114K | 700 |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 4K | $102.39 | $358K | 2K |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 7K | $101.37 | $686K | 5K |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 8K | $100.43 | $796K | 12K |
| 2026-09-17 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 20K | $17.88 | $358K | 20K |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Sell | 13K | $106.74 | $1.4M | 4K |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Sell | 7K | $106.25 | $767K | 17K |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Sell | 3K | $105.19 | $273K | 25K |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 9K | $22.07 | $207K | 27K |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 6K | $21.77 | $136K | 18K |
| 2026-09-01 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 8K | $17.88 | $134K | 12K |
| 2026-08-19 | Read Simon | Director | Sell | 3K | $117.55 | $327K | 0 |
| 2026-08-19 | Read Simon | Director | Exercise or conversion | 3K | $18.36 | $51K | 3K |
| 2026-08-13 | Veness Adam M | SVP, General Counsel and Sec. | Exercise or conversion | 15K | $18.17 | $273K | 15K |
| 2026-08-10 | McGeorge Anne | Director | Sell | 700 | $111.41 | $78K | 0 |
| 2026-08-10 | McGeorge Anne | Director | Sell | 1K | $110.64 | $111K | 700 |
| 2026-08-10 | McGeorge Anne | Director | Sell | 2K | $109.30 | $197K | 2K |
| 2026-08-10 | McGeorge Anne | Director | Sell | 3K | $108.38 | $303K | 4K |
| 2026-08-10 | McGeorge Anne | Director | Sell | 1K | $107.58 | $156K | 6K |
| 2026-08-10 | McGeorge Anne | Director | Exercise or conversion | 7K | $11.20 | $73K | 8K |
| 2026-08-10 | McGeorge Anne | Director | Exercise or conversion | 1K | $19.36 | $24K | 1K |
| 2026-08-10 | Veness Adam M | SVP, General Counsel and Sec. | Sell | 16K | $110.38 | $1.8M | 0 |
| 2026-08-10 | Veness Adam M | SVP, General Counsel and Sec. | Exercise or conversion | 16K | $17.88 | $289K | 16K |
| 2026-08-10 | Read Simon | Director | Sell | 397 | $111.77 | $44K | 0 |
| 2026-08-10 | Read Simon | Director | Sell | 470 | $111.05 | $52K | 397 |
| 2026-08-10 | Read Simon | Director | Sell | 272 | $109.96 | $30K | 867 |
| 2026-08-10 | Read Simon | Director | Sell | 831 | $108.95 | $91K | 1K |
| 2026-08-10 | Read Simon | Director | Sell | 737 | $108.17 | $80K | 2K |
| 2026-08-10 | Read Simon | Director | Sell | 70 | $107.11 | $7K | 3K |
| 2026-08-10 | Read Simon | Director | Exercise or conversion | 3K | $18.36 | $51K | 3K |
| 2026-08-07 | Veness Adam M | SVP, General Counsel and Sec. | Sell | 616 | $111.18 | $68K | 0 |
| 2026-08-07 | Veness Adam M | SVP, General Counsel and Sec. | Sell | 3K | $110.61 | $356K | 616 |
| 2026-08-07 | Veness Adam M | SVP, General Counsel and Sec. | Exercise or conversion | 4K | $17.88 | $69K | 4K |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Sell | 22K | $108.72 | $2.4M | 65K |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Sell | 104K | $107.96 | $11.2M | 87K |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Sell | 800 | $110.76 | $89K | 191K |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Sell | 3K | $110.02 | $279K | 192K |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Sell | 2K | $109.10 | $259K | 195K |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Sell | 24K | $108.05 | $2.6M | 197K |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Sell | 10K | $107.49 | $1.1M | 221K |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Exercise or conversion | 126K | $8.44 | $1.1M | 231K |
| 2026-08-07 | Garcia Marino | CEO AND PRESIDENT | Exercise or conversion | 40K | $8.44 | $338K | 105K |
| 2026-07-09 | Savitz Ryan | EVP, CFO & CBO | Sell | 6K | $101.97 | $568K | 0 |
| 2026-07-09 | Savitz Ryan | EVP, CFO & CBO | Sell | 15K | $101.24 | $1.6M | 6K |
| 2026-07-09 | Savitz Ryan | EVP, CFO & CBO | Sell | 10K | $100.22 | $1.0M | 21K |
| 2026-07-09 | Savitz Ryan | EVP, CFO & CBO | Exercise or conversion | 31K | $21.77 | $680K | 31K |
| 2026-06-17 | Veness Adam M | SVP, General Counsel and Sec. | Sell | 17K | $80.34 | $1.3M | 13K |
| 2026-06-17 | Veness Adam M | SVP, General Counsel and Sec. | Exercise or conversion | 30K | $17.88 | $536K | 30K |
| 2026-06-17 | Veness Adam M | SVP, General Counsel and Sec. | Sell | 13K | $81.38 | $1.1M | 0 |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Sell | 4K | $91.37 | $380K | 4K |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Sell | 17K | $90.72 | $1.5M | 8K |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Sell | 5K | $89.72 | $487K | 25K |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 9K | $22.07 | $207K | 31K |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 6K | $21.77 | $136K | 21K |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 7K | $17.88 | $124K | 15K |
| 2026-06-01 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 4K | $8.44 | $34K | 8K |
| 2026-05-08 | Soteropoulos Paula | Director | Sell | 599 | $85.47 | $51K | 0 |
| 2026-05-08 | Soteropoulos Paula | Director | Exercise or conversion | 599 | $8.44 | $5K | 599 |
| 2026-04-09 | Savitz Ryan | EVP, CFO & CBO | Sell | 8K | $89.84 | $739K | 0 |
| 2026-04-09 | Savitz Ryan | EVP, CFO & CBO | Exercise or conversion | 8K | $17.88 | $147K | 8K |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Sell | 7K | $85.54 | $619K | 0 |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Sell | 19K | $84.57 | $1.6M | 7K |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Sell | 60K | $83.90 | $5.0M | 27K |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Sell | 2K | $82.84 | $196K | 87K |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Sell | 800 | $81.36 | $65K | 89K |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Sell | 1K | $80.25 | $119K | 90K |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Sell | 22K | $78.86 | $1.7M | 91K |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Sell | 1K | $78.33 | $109K | 113K |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Exercise or conversion | 40K | $17.88 | $715K | 114K |
| 2026-03-31 | Savitz Ryan | EVP, CFO & CBO | Exercise or conversion | 74K | $8.44 | $628K | 74K |
| 2026-03-31 | Soteropoulos Paula | Director | Sell | 599 | $80.11 | $48K | 0 |
| 2026-03-31 | Soteropoulos Paula | Director | Exercise or conversion | 599 | $8.44 | $5K | 599 |
| 2026-03-24 | Soteropoulos Paula | Director | Sell | 28K | $78.05 | $2.2M | 0 |
| 2026-03-24 | Soteropoulos Paula | Director | Exercise or conversion | 28K | $8.44 | $233K | 28K |
| 2026-03-16 | Garcia Marino | CEO AND PRESIDENT | Exercise or conversion | 6K | $17.88 | $100K | 65K |
| 2026-03-16 | Garcia Marino | CEO AND PRESIDENT | Exercise or conversion | 60K | $6.70 | $400K | 60K |
| 2026-03-12 | Randhawa Simrat | EVP, Head of R&D | Sell | 34K | $81.48 | $2.8M | 0 |
| 2026-03-12 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 13K | $22.07 | $276K | 34K |
| 2026-03-12 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 8K | $21.77 | $181K | 21K |
| 2026-03-12 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 5K | $17.88 | $89K | 13K |
| 2026-03-12 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 8K | $8.44 | $68K | 8K |
| 2026-03-12 | Garcia Marino | CEO AND PRESIDENT | Sell | 900 | $85.53 | $77K | 0 |
| 2026-03-12 | Garcia Marino | CEO AND PRESIDENT | Sell | 200 | $83.38 | $17K | 900 |
| 2026-03-12 | Garcia Marino | CEO AND PRESIDENT | Sell | 13K | $82.60 | $1.1M | 1K |
| 2026-03-12 | Garcia Marino | CEO AND PRESIDENT | Sell | 66K | $81.74 | $5.4M | 14K |
| 2026-03-12 | Garcia Marino | CEO AND PRESIDENT | Sell | 44K | $80.69 | $3.5M | 79K |
| 2026-03-12 | Garcia Marino | CEO AND PRESIDENT | Exercise or conversion | 123K | $6.70 | $824K | 123K |
| 2026-03-12 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 300 | $85.53 | $26K | 0 |
| 2026-03-12 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 200 | $83.38 | $17K | 300 |
| 2026-03-12 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 4K | $82.66 | $319K | 500 |
| 2026-03-12 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 23K | $81.75 | $1.9M | 4K |
| 2026-03-12 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Sell | 16K | $80.71 | $1.3M | 28K |
| 2026-03-12 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 10K | $21.77 | $218K | 44K |
| 2026-03-12 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 18K | $22.07 | $386K | 34K |
| 2026-03-12 | CARR EDWARD | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 16K | $17.88 | $289K | 16K |
| 2025-12-04 | Savitz Ryan | CFO & CBO | Sell | 20K | $45.18 | $904K | 0 |
| 2025-12-04 | Savitz Ryan | CFO & CBO | Exercise or conversion | 20K | $8.44 | $169K | 20K |
| 2025-11-14 | Randhawa Simrat | EVP, Head of R&D | Sell | 109K | $38.14 | $4.2M | 4K |
| 2025-11-14 | Randhawa Simrat | EVP, Head of R&D | Exercise or conversion | 31K | $22.07 | $690K | 113K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON20 Form 144 notices on file for DNTH worth $71.8M at the prices reported; 8 in the last 90 days worth $26.2M. Latest: EDWARD CARR filed on 2026-09-17 to sell 20,000 shares ($2.0M) from 2026-09-17.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-17 | EDWARD CARROfficer | 20K | $2.0M | 0.036% | 2026-09-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-01 | SIMRAT RANDHAWAOfficer | 23K | $2.4M | 0.041% | 2026-09-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-10 | Read SimonOfficer | 6K | $624K | 0.010% | 2026-08-10 | Jefferies LLC |
| 2026-08-10 | ADAM VENESSOfficer | 16K | $1.8M | 0.029% | 2026-08-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-10 | ANNE M MCGEORGEDirector | 8K | $844K | 0.014% | 2026-08-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-07 | MARINO GARCIADirector, Officer | 40K | $4.4M | 0.072% | 2026-08-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-07 | ADAM VENESSOfficer | 4K | $421K | 0.007% | 2026-08-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-07 | MARINO GARCIAOfficer | 126K | $13.6M | 0.225% | 2026-08-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-09 | RYAN SAVITZOfficer | 31K | $3.1M | 0.057% | 2026-07-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-17 | ADAM M VENESSOfficer | 30K | $2.4M | 0.055% | 2026-06-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | SIMRAT RANDHAWAOfficer | 27K | $2.5M | 0.049% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-09 | RYAN SAVITZOfficer | 8K | $719K | 0.018% | 2026-04-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-31 | RYAN SAVITZOfficer | 114K | $9.1M | 0.257% | 2026-03-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-31 | PAULA C SOTEROPOULOSDirector | 1K | $95K | 0.003% | 2026-03-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-24 | PAULA C SOTEROPOULOSDirector | 28K | $2.2M | 0.062% | 2026-03-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-12 | MARINO GARCIADirector, Officer | 123K | $10.6M | 0.276% | 2026-03-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-12 | SIMRAT RANDHAWAOfficer | 34K | $2.9M | 0.076% | 2026-03-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-12 | EDWARD CARROfficer | 44K | $3.7M | 0.098% | 2026-03-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-04 | RYAN SAVITZOfficer | 20K | $879K | 0.047% | 2025-12-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-13 | SIMRAT RANDHAWAOfficer | 197K | $7.6M | 0.458% | 2025-11-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON9 holders report 5% or more of DNTH in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (5,970,638 shares), filed 2025-11-05 for an event on 2025-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-30 | 13G | Vanguard Capital Managementinvestment adviser | 2.8M | 5.1% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 1 | Alex Silversteinparent holding company, individual | 1.7M | 3.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Sirenia Capital Management LPinvestment adviser, partnership | 1.7M | 3.1% | 2026-06-30 |
| 2026-08-13 | 13G | Wellington Investment Advisors Holdings LLPparent holding company | 3.2M | 5.9% | 2026-06-30 |
| 2026-08-13 | 13G | Wellington Management Group LLPparent holding company | 3.2M | 5.9% | 2026-06-30 |
| 2026-08-13 | 13G | Wellington Group Holdings LLPparent holding company | 3.2M | 5.9% | 2026-06-30 |
| 2026-08-13 | 13G | Wellington Management Company LLPinvestment adviser | 3.2M | 5.5% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 1 | T. Rowe Price Investment Management, Inc.investment adviser | 6.6M | 12.1% | 2026-07-31 |
| 2026-07-28 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 3.5M | 6.4% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 5 | RA Capital Management, L.P.investment adviser, partnership | 2.6M | 4.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Peter Kolchinskyparent holding company, individual | 2.6M | 4.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | Rajeev Shahparent holding company, individual | 2.6M | 4.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | RA Capital Healthcare Fund, L.P.partnership | 2.6M | 4.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Point72 Asset Management, L.P.partnership | 644K | 1.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Point72 Capital Advisors, Inc.corporation | 644K | 1.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Steven A. Cohenindividual | 644K | 1.2% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 3 | Ting Jiaparent holding company, individual | 1.9M | 3.6% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 3 | Octagon Capital Advisors LPinvestment adviser, partnership | 1.9M | 3.6% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 3 | Octagon Investments Master Fund LPpartnership, other entity | 1.7M | 3.0% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 3 | Octagon Biotech Opportunities Fund I LPpartnership, other entity | 292K | 0.6% | 2026-03-31 |
| 2025-11-25 | 13D/Ano. 4 | Tomas Kiselakindividual | 2.1M | 4.9% | 2025-11-21 |
| 2025-11-25 | 13D/Ano. 4 | Fairmount Funds Management LLCinvestment adviser | 2.1M | 4.9% | 2025-11-21 |
| 2025-11-25 | 13D/Ano. 4 | Fairmount Healthcare Fund II L.P.partnership | 2.1M | 4.9% | 2025-11-21 |
| 2025-11-25 | 13D/Ano. 4 | Peter Evan Harwinindividual | 2.1M | 4.9% | 2025-11-21 |
| 2025-11-19 | 13D/Ano. 3 | Michael Gregoryindividual, parent holding company | 2.1M | 4.9% | 2025-11-17 |
| 2025-11-19 | 13D/Ano. 3 | Avidity Partners Management LPinvestment adviser, partnership | 2.1M | 4.9% | 2025-11-17 |
| 2025-11-19 | 13D/Ano. 3 | Avidity Partners Management (GP) LLCparent holding company, other entity | 2.1M | 4.9% | 2025-11-17 |
| 2025-11-19 | 13D/Ano. 3 | Avidity Capital Partners Fund (GP) LPpartnership | 2.1M | 4.9% | 2025-11-17 |
| 2025-11-19 | 13D/Ano. 3 | Avidity Capital Partners (GP) LLCother entity | 2.1M | 4.9% | 2025-11-17 |
| 2025-11-19 | 13D/Ano. 3 | Avidity Private Master Fund I LPpartnership | 1.9M | 4.4% | 2025-11-17 |
| 2025-11-14 | 13G/Ano. 2 | Octagon Private Opportunities Fund II LPpartnership, other entity | 292K | 0.7% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | BCLS Fund III Investments, LPpartnership | 1.3M | 3.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | David Kroinparent holding company, individual | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Ryan Wilderparent holding company, individual | 1.2M | 3.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Vestal Point Capital, LPinvestment adviser, partnership | 1.2M | 3.0% | 2025-09-30 |
| 2025-11-05 | 13G/Ano. 2 | FMR LLCparent holding company | 6.0M | 15.0% | 2025-09-30 |
| 2025-11-05 | 13G/Ano. 2 | Abigail P. Johnsonindividual | 6.0M | 15.0% | 2025-09-30 |
| 2025-09-15 | 13D/Ano. 3 | Fairmount SPV III, LLCother entity | 0 | 0.0% | 2025-09-11 |
13F holders
Tracked managers holding DNTH at their latest 13F. JSON6 of the 30 tracked managers held DNTH at their latest 13F, $121.2M in total at quarter-end prices. Citadel Advisors is the largest at $95.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 975K | $95.0M | 0.01% | -636K |
| Two Sigma Investments | 2026-06-30 | 107K | $10.5M | 0.01% | new |
| Millennium Management | 2026-06-30 | 92K | $9.0M | 0.00% | -170K |
| D. E. Shaw & Co. | 2026-06-30 | 43K | $4.2M | 0.00% | -107K |
| Fisher Asset Management | 2026-06-30 | 23K | $2.3M | 0.00% | +11K |
| AQR Capital Management | 2026-06-30 | 3K | $290K | 0.00% | -1K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$129.1M of operating cash flow.
- Cash
- $110.5M
- Equity
- $1.17B
- Total assets
- $1.21B
- Shares outstanding
- 55,934,378
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$50.2M | n/a | -0.90 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$40.8M | n/a | -0.85 |
| Q4 FY 2025derived | 2025-12-31 | $284K | -$64.4M | -22687.3% | n/a |
| Q3 FY 2025 | 2025-09-30 | $396K | -$36.8M | -9284.1% | -0.97 |
| Q2 FY 2025 | 2025-06-30 | $193K | -$31.6M | -16388.1% | -0.88 |
| Q1 FY 2025 | 2025-03-31 | $1.2M | -$29.5M | -2537.5% | -0.82 |
| Q4 FY 2024derived | 2024-12-31 | $1.3M | -$28.4M | -2144.8% | n/a |
| Q3 FY 2024 | 2024-09-30 | $2.2M | -$25.2M | -1159.0% | -0.74 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2.0M | -$162.3M | -$129.1M | $213K | n/a | n/a |
| FY 2024 | 2024-12-31 | $6.2M | -$85.0M | -$78.2M | $105K | n/a | n/a |
| FY 2023 | 2023-12-31 | $2.8M | -$43.6M | -$36.9M | $110K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$28.5M | -$29.1M | $314K | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$71.1M | -$59.5M | $1.3M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Dianthus Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Dianthus Therapeutics (DNTH), SEC CIK 1690585, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-07.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-17.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-17.JSON and CSV
- Company record
- EDGAR filing index for CIK 1690585Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of DNTH is sold short?
8,986,958 shares were held short at the 2026-10-15 settlement, 10.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is DNTH's daily short volume?
On 2026-11-02, 153,302 of the 259,334 DNTH shares reported to FINRA were sold short, 59.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does DNTH have fails to deliver?
The SEC's latest file shows 176 DNTH shares failed to deliver at settlement 2026-10-07. Fails are reported per settlement date and published twice a month with a lag.
Are DNTH insiders buying or selling?
Insiders at DNTH reported 30 open-market sells worth $26.1M in the last 90 days and no open-market buys. Latest filing: CARR EDWARD (CHIEF ACCOUNTING OFFICER) on 2026-09-17.
Have DNTH insiders filed to sell?
20 Form 144 notices on file for DNTH worth $71.8M at the prices reported; 8 in the last 90 days worth $26.2M. Latest: EDWARD CARR filed on 2026-09-17 to sell 20,000 shares ($2.0M) from 2026-09-17.
Who owns 5% or more of DNTH?
9 holders report 5% or more of DNTH in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 15.0% of the class (5,970,638 shares), filed 2025-11-05 for an event on 2025-09-30.
What did DNTH report last quarter?
In FY 2025 it generated -$129.1M of operating cash flow.
Which tracked 13F managers own DNTH?
6 of the 30 tracked 13F managers held DNTH shares at their latest filing, $121.2M in all. The largest: Ken Griffin's Citadel Advisors (975K shares, $95.0M), Two Sigma Investments (107K shares, $10.5M), Izzy Englander's Millennium Management (92K shares, $9.0M), D. E. Shaw & Co. (43K shares, $4.2M), Ken Fisher's Fisher Asset Management (23K shares, $2.3M), Cliff Asness's AQR Capital Management (3K shares, $290K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.